Nabriva reports successful Phase I clinical trial for BC-3781
Studies presented at ECCMID alongside other papers relating to Nabriva’s pleuromutilin pipeline
Nabriva Therapeutics announced that it has successfully completed a series of Phase I clinical trials of its pleuromutilin antibiotic, BC-3781. BC-3781 is being developed for intravenous and oral treatment of skin and skin structure infections (SSSI) and community-acquired pneumonia (CAP). Data from some of these Phase I trials is being presented at the 20th European Congress of Clinical microbiology and infectious diseases (ECCMID) in Vienna.
The results of the clinical trials which began in July 2009 demonstrate that BC-3781 was safe and well tolerated up to the maximum doses tested. BC-3781 exhibits predictable pharmacokinetics in humans and the plasma levels achieved show that it has therapeutic potential for the treatment of skin and lung infections caused by bacteria. Nabriva will now progress BC-3781 into Phase II studies.
Dr. David Chiswell, CEO of Nabriva Therapeutics said: "BC-3781 is the first pleuromutilin to demonstrate safety, tolerability and therapeutic drug levels when administered systemically in humans. The phase I data show that BC-3781 can be delivered either orally or by intravenous infusion and that it has real potential to treat serious bacterial infections including those caused by organisms resistant to other antibiotics including MRSA and MDRP. We look forward to advancing clinical development into Phase II trials shortly.”
Other news from the department research and development
